At Curigin, we are developing innovative therapies using our novel bi-specific shRNA technology to simultaneously knockdown two different disease causing pathways.
Our lead pipelines target cancer pathways such as mTOR and STAT3 and deliver our bi-specific shRNA through an oncolytic virus genetically engineered to exclusively target and replicate in cancer cells.
Our lead pipelines target cancer pathways such as mTOR and STAT3 and deliver our bi-specific shRNA through an oncolytic virus genetically engineered to exclusively target and replicate in cancer cells.
Location: South Korea, Seoul
Employees: 11-50